IMMUTEP Ltd

IMMP chart

IMMUTEP Ltd news

• Immutep Files Appendix 4G Confirming Corporate Governance Compliance for FY Ending 30 June 2026

  Kalkine Media · Oct 27, 1:01 AM EDT

• Immutep Schedules 2026 AGM for 27 November with Director Re-Elections and 10% Placement Capacity on Agenda

  Kalkine · Oct 26, 10:43 PM EDT

• Immutep Lodges Appendix 4G Corporate Governance Key to Disclosures for Financial Year Ended 30 June 2026

  Kalkine · Oct 26, 10:36 PM EDT

• Immutep Annual Report FY26: TACTI-004 Trial Discontinued, FDA Orphan Drug Designation Granted for Efti in Soft Tissue Sarcoma

  Kalkine · Oct 26, 10:30 PM EDT

• Immutep Limited Files Annual Form 20-F with SEC for Fiscal Year Ended June 30, 2026

  Kalkine · Oct 25, 7:15 PM EDT

• What does ESMO mean for Immutep (ASX:IMM) right now?

  Kalkine Media · Oct 25, 5:59 PM EDT

• Immutep presents HRQoL data from EFTISARC-NEO trial

  TipRanks · Oct 23, 9:01 AM EDT

• Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026

  Yahoo Finance · Oct 23, 8:00 AM EDT

• Immutep FY2026 Annual Report Reveals ADS Ratio Increase to 200 Shares

  Kalkine Media · Oct 23, 6:22 AM EDT

• A lung cancer trial was discontinued as Immutep (NASDAQ: IMMP) posted a wider annual loss.

  Stock Titan · Oct 23, 6:20 AM EDT

• Immutep Presents EFTISARC-NEO Quality of Life Data at ESMO 2026, Showing Post-Surgery Improvement

  Kalkine · Oct 23, 2:02 AM EDT

• Enterprise value to EBITDA forward of Immutep Ltd – LSX:A2H81H

  TradingView · Oct 20, 9:47 PM EDT

IMMUTEP Ltd key financials

No XBRL financial data is available for this company yet.

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 20-F20-F2026-10-23
• 6-K6-K2026-10-14
• 6-K6-K2026-09-22
• 6-K6-K2026-09-11
• 6-K6-K2026-09-02
• 6-K6-K2026-08-03
• 6-K6-K2026-07-14
• 6-K6-K2026-06-05
• 6-K6-K2026-05-01
• 6-K6-K2026-05-01
• 6-K6-K2026-04-16
• 6-K6-K2026-03-20

About IMMUTEP Ltd

Ticker

IMMP (Nasdaq)

Industry

Pharmaceutical Preparations

Headquarters

Sydney,, Australia

Incorporated in

Australia

Fiscal year end

June 30

SEC CIK

1506184

Former names

Prima BioMed Ltd

Frequently asked questions